[go: up one dir, main page]

PE20090229A1 - DIFENIL-DIHIDRO-IMIDAZOPIRIDINONAS COMO INHIBIDORES DE LA INTERACCION DE MDM2 CON EL PEPTIDO p-53 - Google Patents

DIFENIL-DIHIDRO-IMIDAZOPIRIDINONAS COMO INHIBIDORES DE LA INTERACCION DE MDM2 CON EL PEPTIDO p-53

Info

Publication number
PE20090229A1
PE20090229A1 PE2008000636A PE2008000636A PE20090229A1 PE 20090229 A1 PE20090229 A1 PE 20090229A1 PE 2008000636 A PE2008000636 A PE 2008000636A PE 2008000636 A PE2008000636 A PE 2008000636A PE 20090229 A1 PE20090229 A1 PE 20090229A1
Authority
PE
Peru
Prior art keywords
dihydro
imidazo
chloro
bis
phenyl
Prior art date
Application number
PE2008000636A
Other languages
English (en)
Inventor
Romyr Dominique
Robert Alan Goodnow Jr
Qi Qiao
Binh Thanh Vu
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20090229A1 publication Critical patent/PE20090229A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

REFERIDA A UN DERIVADO DE IMIDAZOPIRIDINONA DE FORMULA (1), DONDE Y1 E Y2 SON HALOGENO, TRIFLUOROMETILO, NO2, CIANO, ENTRE OTROS; X ES SO2, CO O C=OCH2; R1 ES H, ALQUILO SUSTITUIDO POR HETEROCICLO, ENTRE OTROS; R2 ES ALQUILO, ARILO, HETEROARILO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: 5-[RAC-CIS-2,3-BIS-(4-CLORO-FENIL)-5-OXO-2,3-DIHIDRO-5H-IMIDAZO[1,2-a]PIRIDINA-1-SULFONIL]-2-FLUOR-BENZONITRILO, 5-[2R*,3S*-BIS-(4-CLORO-FENIL)-5-OXO-2,3-DIHIDRO-5H-IMIDAZO[1,2-a]PIRIDINA-1-SULFONIL]-2-FLUOR-BENZONITRILO, RAC-CIS-2,3-BIS-(4-CLORO-FENIL)-1-(2,4-DIFLUOR-BENCENOSULFONIL)-2,3-DIHIDRO-1H-IMIDAZO[1,2-a]PIRIDIN-5-ONA, ENTRE OTROS. TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS INHIBEN LA INTERACCION DE LA PROTEINA MDM2 CON UN PEPTIDO DE TIPO p-53 Y SON UTILES EN EL TRATAMIENTO DE ENFERMEDADES PROLIFERATIVAS
PE2008000636A 2007-04-12 2008-04-10 DIFENIL-DIHIDRO-IMIDAZOPIRIDINONAS COMO INHIBIDORES DE LA INTERACCION DE MDM2 CON EL PEPTIDO p-53 PE20090229A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US92311007P 2007-04-12 2007-04-12

Publications (1)

Publication Number Publication Date
PE20090229A1 true PE20090229A1 (es) 2009-03-27

Family

ID=39478351

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008000636A PE20090229A1 (es) 2007-04-12 2008-04-10 DIFENIL-DIHIDRO-IMIDAZOPIRIDINONAS COMO INHIBIDORES DE LA INTERACCION DE MDM2 CON EL PEPTIDO p-53

Country Status (18)

Country Link
US (1) US7625895B2 (es)
EP (1) EP2146986B1 (es)
JP (1) JP2010523616A (es)
KR (1) KR20090118116A (es)
CN (1) CN101657449B (es)
AR (1) AR066014A1 (es)
AT (1) ATE514696T1 (es)
AU (1) AU2008238062A1 (es)
BR (1) BRPI0810495A2 (es)
CA (1) CA2684008A1 (es)
CL (1) CL2008001047A1 (es)
ES (1) ES2367228T3 (es)
IL (1) IL201021A0 (es)
MX (1) MX2009011019A (es)
PE (1) PE20090229A1 (es)
RU (1) RU2009141522A (es)
TW (1) TW200848033A (es)
WO (1) WO2008125487A1 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2011134283A (ru) 2009-01-16 2013-02-27 Дайити Санкио Компани, Лимитед Имидазотиазольные производные, имеющие пролиновую циклическую структуру
EP2499145B1 (en) 2009-11-12 2016-01-27 The Regents Of The University Of Michigan Spiro-oxindole mdm2 antagonists
US10159669B2 (en) * 2010-03-02 2018-12-25 Ian H. Chan Individual and combination of mdivi-1 and nutlin-3 for topical or intravitreal ophthalmic use
JO2998B1 (ar) 2010-06-04 2016-09-05 Amgen Inc مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان
FR2967072B1 (fr) 2010-11-05 2013-03-29 Univ Dundee Procede pour ameliorer la production de virus et semences vaccinales influenza
UY33725A (es) 2010-11-12 2012-06-29 Sanofi Sa Antagonistas de mdm2 de espiro-oxindol
CN103717605B (zh) 2011-05-11 2016-05-18 密执安州立大学董事会 螺-羟吲哚mdm2拮抗剂
JP6093770B2 (ja) 2011-09-27 2017-03-08 アムジエン・インコーポレーテツド 癌の治療のためのｍｄｍ２阻害剤としての複素環化合物
KR102196882B1 (ko) 2012-12-20 2020-12-30 머크 샤프 앤드 돔 코포레이션 Hdm2 억제제로서의 치환된 이미다조피리딘
US11407721B2 (en) 2013-02-19 2022-08-09 Amgen Inc. CIS-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer
WO2014134201A1 (en) 2013-02-28 2014-09-04 Amgen Inc. A benzoic acid derivative mdm2 inhibitor for the treatment of cancer
MX374513B (es) 2013-03-14 2025-03-06 Amgen Inc Compuestos de morfolinona de ácido heteroarilo como inhibidores mdm2 para el tratamiento de cáncer.
JOP20200296A1 (ar) 2013-06-10 2017-06-16 Amgen Inc عمليات صنع وأشكال بلورية من mdm2 مثبط
NZ758548A (en) 2013-11-11 2022-02-25 Amgen Inc Combination therapy including an mdm2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
US20190269675A1 (en) 2014-01-28 2019-09-05 Buck Institute for Research and Aging Treatment of parkinson's disease and other conditions caused or mediated by senescent astrocytes using small molecule senolytic agents
SG11201606239UA (en) 2014-01-28 2016-08-30 Buck Inst For Res On Aging Methods and compositions for killing senescent cells and for treating senescence-associated diseases and disorders
US20170216286A1 (en) 2014-01-28 2017-08-03 Mayo Foundation For Medical Education And Research Killing senescent cells and treating senescence-associated conditions using a src inhibitor and a flavonoid
US10328058B2 (en) 2014-01-28 2019-06-25 Mayo Foundation For Medical Education And Research Treating atherosclerosis by removing senescent foam cell macrophages from atherosclerotic plaques
JP7037500B2 (ja) 2016-04-06 2022-03-16 ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン Ｍｄｍ２タンパク質分解剤
JP7001614B2 (ja) 2016-04-06 2022-02-03 ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン リガンド依存性の標的タンパク質分解のための単官能性中間体
ES2858151T3 (es) 2016-05-20 2021-09-29 Hoffmann La Roche Conjugados de PROTAC-anticuerpo y procedimientos de uso
US11046703B2 (en) 2018-10-08 2021-06-29 The Regents Of The University Of Michigan Small molecule MDM2 protein degraders
CA3171258A1 (en) 2020-03-19 2021-09-23 Nan JI Mdm2 degraders and uses thereof
WO2023056069A1 (en) 2021-09-30 2023-04-06 Angiex, Inc. Degrader-antibody conjugates and methods of using same
WO2024240858A1 (en) 2023-05-23 2024-11-28 Valerio Therapeutics Protac molecules directed against dna damage repair system and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2358891A1 (fr) * 1976-07-22 1978-02-17 Yamanouchi Pharma Co Ltd Composes heterocycliques contenant un azote, utilise comme agents analgesiques et anti-inflammatoires
JPH02101065A (ja) 1988-10-06 1990-04-12 Tanabe Seiyaku Co Ltd イミダゾリン誘導体及びその製法
GB9704762D0 (en) 1997-03-07 1997-04-23 Zeneca Ltd Chemical process
GB2351082A (en) 1999-06-18 2000-12-20 Lilly Forschung Gmbh Synthesis of Cyclic Substituted Amidines
ES2301717T3 (es) 2001-12-18 2008-07-01 F. Hoffmann-La Roche Ag Cis-2,4,5-trifenil-imidazolinas y su utilizacion para el tratamiento de tumores.
ES2307822T3 (es) 2001-12-18 2008-12-01 F. Hoffmann-La Roche Ag Cis-imidazolinas como inhibidores de mdm2.
RU2319696C2 (ru) * 2003-06-17 2008-03-20 Ф.Хоффманн-Ля Рош Аг Цис-2, 4, 5-триарил-имидазолины
DE602005011132D1 (de) 2004-05-18 2009-01-02 Hoffmann La Roche Neuartige cis-imidazoline
US7893278B2 (en) 2004-06-17 2011-02-22 Hoffman-La Roche Inc. CIS-imidazolines
CA2636824A1 (en) 2006-01-18 2007-07-26 F. Hoffmann-La Roche Ag Cis-4,5-biaryl-2-heterocyclic-imidazolines as mdm2 inhibitors
US8232298B2 (en) 2006-03-22 2012-07-31 Janssen Pharmaceutica N.V. Inhibitors of the interaction between MDM2 and P53

Also Published As

Publication number Publication date
US20080255119A1 (en) 2008-10-16
ES2367228T3 (es) 2011-10-31
JP2010523616A (ja) 2010-07-15
WO2008125487A1 (en) 2008-10-23
ATE514696T1 (de) 2011-07-15
EP2146986A1 (en) 2010-01-27
MX2009011019A (es) 2009-10-29
CN101657449B (zh) 2012-06-06
RU2009141522A (ru) 2011-05-20
TW200848033A (en) 2008-12-16
CA2684008A1 (en) 2008-10-23
EP2146986B1 (en) 2011-06-29
BRPI0810495A2 (pt) 2018-10-30
US7625895B2 (en) 2009-12-01
CN101657449A (zh) 2010-02-24
KR20090118116A (ko) 2009-11-17
AU2008238062A1 (en) 2008-10-23
CL2008001047A1 (es) 2009-01-16
IL201021A0 (en) 2010-05-17
AR066014A1 (es) 2009-07-15

Similar Documents

Publication Publication Date Title
PE20090229A1 (es) DIFENIL-DIHIDRO-IMIDAZOPIRIDINONAS COMO INHIBIDORES DE LA INTERACCION DE MDM2 CON EL PEPTIDO p-53
PE20210128A1 (es) Inhibidores de la ectonucleotido pirofosfatasa-fosfodiesterasa 1 (enpp-1) y usos de los mismos
PE20081256A1 (es) Triazalopiridacina como modulador de la actividad proteina cinasa
CL2011000846A1 (es) Compuestos heterociclicos sustituidos; composicion farmaceutica; y su uso para el tratamiento de la hepatitis c.
CY1120137T1 (el) Ενεσιμα σκευασματα βοτουλινικης τοξινης
ATE509634T1 (de) Pharmazeutische formulierungen mit incretin- peptid und aprotisch-polarem lösungsmittel
CL2007002689A1 (es) Compuestos derivados de piperidin-1-carboxamida, inhibidores de la renina; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como hipertension, insuficiencia cardiaca, fibrosis cardiaca, entre otras.
PE20090365A1 (es) Imidazopirazinas como inhibidores de proteina quinasa
CL2011001082A1 (es) Compuestos derivados de amino-tetrahidropiranos sustituidos con heterociclos, composicion farmaceutica; y uso en el tratamiento de una afeccion seleccionada de resistencia a la insulina, hiperglicemia y diabetes de tipo 2.
PE20110102A1 (es) Derivados de n-(2-oxo-2-pirrolidinil-1-il)etil-2-amino-acetamida como inhibidores de proteinas de apoptosis (iap)
CL2008001822A1 (es) Compuestos derivados de tiazolo[5,4-b]piridina; composicion farmaceutica que comprende a dichos compuestos; y uso del compuesto en el tratamiento de la resistencia a la insulina, sindrome metabolico, diabetes, entre otras.
PE20061436A1 (es) Derivados de amida sustituida como inhibidores de proteina quinasa
PE20090816A1 (es) Derivados de pirrolopirimidinona como agentes ligandos de los receptores p2x3
CO6300954A2 (es) Derivados de tienopiridinonas como activadores de proteina quinasa activados por ampk
EA201170772A1 (ru) Органические соединения
CL2008001994A1 (es) Compuestos derivados de pirazin-2-ona; combinacion farmaceutica; y uso en el tratamiento de enfermedades tales como diabetes, aterosclerosis, hipertension, entre otras.
EA200900184A1 (ru) 4-амино-4-оксобутаноиловые пептиды как ингибиторы вирусной репликации
CL2004000234A1 (es) Compuestos derivados 3-(piridin-2-il)-4-heteroaril-pirazol sustituidos, antagonistas de aik5 y/o aik4; composicion farmaceutica y uso del compuesto en el tratamiento de desordenes fibroticos como esclerodermia, lupus nefritico, cicatrizacion de herid
CY1115767T1 (el) 1η-κιναζολινο-2,4-διονες
CL2004001069A1 (es) Compuestos derivados de 1-benzoil-isoquinolinas sustituidos; procedimiento de preparacion, composicion farmaceutica; y uso para el tratamiento o profilaxis de diabetes tipo ii.
PE20071094A1 (es) Derivados 1-ortoflurofenil sustituidos 1,2,5-tiadiazolidindionas como inhibidores de ptpasa
PE20080677A1 (es) Inhibidores de pirrolotriazina cinaza
PE20090511A1 (es) Imidazopiridinonas
EA200901157A1 (ru) Конденсированные кольцевые гетероциклические модуляторы киназы
PE20060334A1 (es) Derivados de piridina como antagonistas del receptor a2b de adenosina

Legal Events

Date Code Title Description
FC Refusal